

DESCRIPTION


Species Reactivity	Human
Specificity	Detects human IL-5 based on Mepolizumab therapeutic antibody.
Source	Recombinant Monoclonal Human IgG ₁ Clone # Hu212
Purification	Protein A or G purified from cell culture supernatant
Immunogen	Human IL-5
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

ELISA This antibody functions as an ELISA detection antibody for the specific antigen in direct ELISA. Colorimetric detection is performed after addition of a suitable substrate.

DATA



PREPARATION AND STORAGE

Reconstitution	Reconstitute at 0.5 mg/mL in sterile PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	<p>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</p> <ul style="list-style-type: none"> • 12 months from date of receipt, -20 to -70 °C as supplied. • 1 month, 2 to 8 °C under sterile conditions after reconstitution. • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

BACKGROUND

Mepolizumab is a humanized IgG1 k anti-IL5 monoclonal antibody. IL-5 is a key cytokine required for the maturation, activation, proliferation and survival of eosinophils making it an ideal target for therapeutic management of eosinophil levels in respiratory indications. Mechanistically, mepolizumab exerts its therapeutic function as an IL-5 antagonist to reduce eosinophil levels in the blood. IL-5 is 134-amino acid 52 kDa homodimeric protein with a four-helix domain. Mepolizumab specifically binds to the α-chain of IL-5, resulting in two IL-5 dimers being cross-linked by two molecules of mepolizumab. The highly specific binding of mepolizumab to IL-15 blocks ligation to IL-5Aa receptor. The biologic is primarily used for the management of moderate to severe asthma. Bio-Techne's Leronlimab biosimilar is produced using the full-length sequence which is identical to that of the original therapeutic antibody.